CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study

BACKGROUND: Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) (K3)—a novel synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a potential Th1-type immune response against cancer cells. We conducted a phase I study of CpG ODN (K3) in patients with lung cancer to as...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsuka, Tomoyuki, Nishida, Sumiyuki, Shibahara, Takayuki, Temizoz, Burcu, Hamaguchi, Masanari, Shiroyama, Takayuki, Kimura, Keiko, Miyake, Kotaro, Hirata, Haruhiko, Mizuno, Yumiko, Yagita, Mayu, Manabe, Yusuke, Kuroda, Etsushi, Takeda, Yoshito, Kida, Hiroshi, Ishii, Ken J., Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264631/
https://www.ncbi.nlm.nih.gov/pubmed/35799134
http://dx.doi.org/10.1186/s12885-022-09818-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264631/
https://www.ncbi.nlm.nih.gov/pubmed/35799134
http://dx.doi.org/10.1186/s12885-022-09818-4

Ejemplares similares